Anavex Life Sciences Corp.
(NASDAQ : AVXL)

( )
AVXL PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Binary Options?
We'll teach you the best ways to trade binaries.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
BIIBBiogen Inc.
1.31%353.031.2%$871.11m
AMGNAmgen Inc.
-0.53%194.881.2%$564.77m
CELGCelgene Corporation
-0.54%85.231.2%$555.79m
GILDGilead Sciences, Inc.
-0.16%77.260.9%$499.41m
SRPTSarepta Therapeutics, Inc.
-1.97%136.6816.6%$376.94m
VRTXVertex Pharmaceuticals Incorporated
0.40%181.221.9%$331.68m
REGNRegeneron Pharmaceuticals, Inc.
-0.79%364.752.6%$305.25m
ILMNIllumina, Inc.
-1.63%301.993.5%$267.19m
BLUEBluebird Bio, Inc.
-1.83%177.3015.7%$219.07m
NKTRNektar Therapeutics
0.00%47.795.6%$188.00m
ALXNAlexion Pharmaceuticals, Inc.
-0.95%134.582.0%$175.68m
FMIFoundation Medicine, Inc.
0.00%136.708.8%$168.36m
EXASExact Sciences Corporation
1.41%64.6625.4%$159.06m
BMRNBioMarin Pharmaceutical Inc.
-0.85%102.734.4%$138.72m
EXELExelixis, Inc.
-3.61%21.076.4%$137.74m

Company Profile

Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.